Investigations into the lymphopaenic and immunosuppressive properties of the antitumour agent, mitoclomine.
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001854:Bone Marrow Cells; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008099:Liver / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects; D008231:Lymphopenia / Q000139:chemically induced; D051379:Mice; D009150:Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D013154:Spleen / Q000473:pathology; D013950:Thymus Gland / Q000473:pathology; D014812:Vitamin K / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D009150:Mustard Compounds; D009588:Nitrogen Mustard Compounds; D014812:Vitamin K